ArticleJournal of neuro-oncology2002
Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
Article in Journal of neuro-oncology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- The role of statins in neurosurgery.Neurosurgical review · 2010Pooled it
- Drug Repositioning for Refractory Benign Tumors of the Central Nervous System.International journal of molecular sciences · 2023Review
- Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Review
- Identification of epithelial membrane protein 2 (EMP2) as a molecular marker and correlate for angiogenesis in meningioma.Journal of neuro-oncology · 2020Article
- Drug Solubility Enhancement through the Preparation of Multicomponent Organic Materials: Eutectics of Lovastatin with Carboxylic Acids.Pharmaceutics · 2019Article
- Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression.Scientific reports · 2018Article
- Article
- Overexpression of RLIP76 Required for Proliferation in Meningioma Is Associated with Recurrence.PloS one · 2015Article
- Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.PloS one · 2013Article
- Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3.Journal of neuro-oncology · 2012Article
- CD133-positive cells might be responsible for efficient proliferation of human meningioma cells.International journal of molecular sciences · 2012Article
- Cytotoxic effects of statins and thiazolidinediones on meningioma cells.Journal of neuro-oncology · 2011Article
- beta-Ionone-induced apoptosis in human osteosarcoma (U2os) cells occurs via a p53-dependent signaling pathway.Molecular biology reports · 2010Article
- Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.Journal of neuro-oncology · 2009Review
- New prospects for management and treatment of inoperable and recurrent skull base meningiomas.Journal of neuro-oncology · 2008Review
- Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts.The Biochemical journal · 2007Article
- Influences of lovastatin on membrane ion flow and intracellular signaling in breast cancer cells.Cellular & molecular biology letters · 2007Article
- Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK.Molecular and cellular biochemistry · 2005Article
- Apoptosis of human gastric adenocarcinoma cells induced by beta-ionone.World journal of gastroenterology · 2004Article
- Transforming growth factor-beta effects on meningioma cell proliferation and signal transduction pathways.Journal of neuro-oncology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lovastatin inhibits 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase the rate limiting enzyme for synthesis of mevalonic acid, a precursor for cholesterol, farnesyl and geranylgeranyl pyrophosphate isoprenoids. Recent studies suggest it also has growth inhibitory properties. Posttranslational farnesyl or geranylgeranylation of low molecular weight GTP-binding proteins such as RAS and RHO are thought to be an essential step in activation of phosphorylation cascades such as the RAS-RAF-1-MEK-1-MAPK/ERK pathway which stimulate cell proliferation. In this study, we evaluated lovastatin effects on meningioma cell proliferation and activation of the MEK-1-MAPK/ERK pathway. The effect of lovastatin on cell proliferation was assessed in eight human meningioma cell cultures stimulated by platelet derived growth factor (PDGF)-BB, cerebrospinal fluid (CSF), and fetal bovine serum (FBS). Concomitant lovastatin effects on phosphorylation/activation of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) kinase (MEK-1) and MAPK/ERK were assessed by Western blot. Whether lovastatin acts via a mevalonate-dependent mechanism was also evaluated. Coadministration of lovastatin completely blocked PDGF-BB, CSF, and FBS stimulation of [3H]-thymidine incorporation and cell proliferation. Lovastatin inhibited PDGF-BB's stimulatory effect in a dose dependent manner. Concomitant with its growth inhibitory effects, lovastatin reduced phosphorylation/activation of MEK-1/2 in five meningiomas and MAPK/ERK in seven. Coadministration of mevalonate with lovastatin partially restored PDGF's mitogenic effect. Lovastatin is a potent inhibitor of meningioma cell proliferation which may act in part by reducing activation of MEK-1-MAPK/ERK pathway. Additional studies are warranted to assess whether lovastatin and similar HMG-CoA reductase inhibitors represent a new adjunctive chemotherapy for recurrent meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.